BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38167707)

  • 1. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
    Landoni E; Woodcock MG; Barragan G; Casirati G; Cinella V; Stucchi S; Flick LM; Withers TA; Hudson H; Casorati G; Dellabona P; Genovese P; Savoldo B; Metelitsa LS; Dotti G
    Nat Commun; 2024 Jan; 15(1):89. PubMed ID: 38167707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-21 Selectively Protects CD62L
    Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
    J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
    Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
    J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
    Ngai H; Barragan GA; Tian G; Balzeau JC; Zhang C; Courtney AN; Guo L; Xu X; Wood MS; Drabek JM; Demberg T; Sands CM; Chauvin-Fleurence CN; Di Pierro EJ; Rosen JM; Metelitsa LS
    Cancer Immunol Res; 2023 Feb; 11(2):171-183. PubMed ID: 36484736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
    Heczey A; Xu X; Courtney AN; Tian G; Barragan GA; Guo L; Amador CM; Ghatwai N; Rathi P; Wood MS; Li Y; Zhang C; Demberg T; Di Pierro EJ; Sher AC; Zhang H; Mehta B; Thakkar SG; Grilley B; Wang T; Weiss BD; Montalbano A; Subramaniam M; Xu C; Sachar C; Wells DK; Dotti G; Metelitsa LS
    Nat Med; 2023 Jun; 29(6):1379-1388. PubMed ID: 37188782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.
    Courtney AN; Tian G; Metelitsa LS
    Blood; 2023 Feb; 141(8):869-876. PubMed ID: 36347021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
    Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
    Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
    Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
    Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
    Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
    Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
    Song L; Asgharzadeh S; Salo J; Engell K; Wu HW; Sposto R; Ara T; Silverman AM; DeClerck YA; Seeger RC; Metelitsa LS
    J Clin Invest; 2009 Jun; 119(6):1524-36. PubMed ID: 19411762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T
    Xhangolli I; Dura B; Lee G; Kim D; Xiao Y; Fan R
    Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):129-139. PubMed ID: 31229590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA
    Trujillo-Ocampo A; Cho HW; Clowers M; Pareek S; Ruiz-Vazquez W; Lee SE; Im JS
    Front Immunol; 2020; 11():567406. PubMed ID: 33329531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.